CDC25B mediates the rapamycin-induced activation of AKT, elF4E and p38 cascades, and CDC25B knockdown promotes the inhibitory effect of rapamycin on cancer cells growth through blocking cell cycle progression and inhibiting oncogenic pathways activation by rapamycin (51). Here, AKT1 is linked to cancer.